PainReform (PRFX) News Today → “Dollar Will Be Worth NOTHING” -Musk (From Crypto 101 Media) (Ad) Free PRFX Stock Alerts $0.80 0.00 (0.00%) (As of 05/16/2024 ET) Add Compare Share Share HeadlinesStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 16 at 5:37 PM | finanznachrichten.dePainReform Ltd: PainReform Provides Business Update for the First Quarter of 2024May 15 at 11:33 PM | msn.comPRFX Stock Earnings: PainReform Misses EPS for Q1 2024May 15 at 4:05 PM | globenewswire.comPainReform Provides Business Update for the First Quarter of 2024May 8, 2024 | globenewswire.comPainReform CEO Ilan Hadar Discusses Latest Developments Related to PRF-110 and its Potential to Help Tackle the Opioid Epidemic on Proactiveinvestors.comApril 18, 2024 | globenewswire.comPainReform Announces Closing of $4 Million Public OfferingApril 16, 2024 | finance.yahoo.comPainReform Announces Pricing of $4 Million Public OfferingApril 9, 2024 | msn.comEXCLUSIVE: PainReform's Non-Opiate Post-Surgical Pain Relief Treatment Outperforms Rival Medicine Under Various Testing ConditionsApril 9, 2024 | finance.yahoo.comPainReform’s Non-Opiate Topical Treatment for Post-Surgical Pain Relief Outperforms Leading Competitor Under Various Testing ConditionsApril 9, 2024 | globenewswire.comPainReform's Non-Opiate Topical Treatment for Post-Surgical Pain Relief Outperforms Leading Competitor Under Various Testing ConditionsApril 4, 2024 | finance.yahoo.comUK watchdog says Theramex-Viatris deal raises competition concernsApril 4, 2024 | markets.businessinsider.comBuy Rating Affirmed for PainReform as PRF-110 Shows Promise in Non-Opioid Pain Management MarketApril 2, 2024 | finance.yahoo.comEXCLUSIVE: PainReform Reaches 50% Enrollment Target For Phase 3 Study For Its Lead Postoperative Pain DrugApril 2, 2024 | globenewswire.comPainReform Reaches 50% Enrollment in the Second Part of its Phase 3 Clinical Trial of PRF-110 in BunionectomyMarch 7, 2024 | markets.businessinsider.comBuy Rating for PainReform’s PRF-110: Promising Non-Opioid Pain Solution Amidst Opioid CrisisMarch 1, 2024 | globenewswire.comPainReform Provides Year-End Business UpdateJanuary 22, 2024 | finance.yahoo.comPainReform to Present at the Microcap Conference in Atlantic CityJanuary 12, 2024 | msn.comPainReform files to sell 968,545 ordinary shares for holdersJanuary 5, 2024 | markets.businessinsider.comBuy Rating for PainReform’s PRF-110: Superior Spreadability Signaling Market AdvantageJanuary 3, 2024 | finance.yahoo.comPainReform Reports Successful Head-to-Head Comparison of PRF-110 Versus Market Leading Post Surgical Analgesia for Extended Postoperative Pain ReliefDecember 26, 2023 | finance.yahoo.comPainReform Announces Exercise of Warrants for Approximately $1.3 Million in Gross ProceedsDecember 19, 2023 | benzinga.comPainReform Stock (NASDAQ:PRFX) Dividends: History, Yield and DatesNovember 19, 2023 | finanznachrichten.dePainReform Ltd: PainReform Provides Business Update for the Third Quarter of 2023November 18, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: PainReform (PRFX) and Tenet Healthcare (THC)November 15, 2023 | finance.yahoo.comPainReform Provides Business Update for the Third Quarter of 2023November 12, 2023 | morningstar.comPainReform Ltd Ordinary Shares PRFXSeptember 12, 2023 | markets.businessinsider.comPainReform (PRFX) Gets a Buy from Maxim GroupSeptember 11, 2023 | finance.yahoo.comPainReform Announces Plans to Commence Second Part of Phase 3 Clinical Trial to Evaluate PRF-110 in Patients Undergoing Bunionectomy Surgery Following Positive FDA Review of Drug Master FileSeptember 7, 2023 | finance.yahoo.comPainReform Selected for Poster Presentation at the 13th Congress of the European Pain Federation in Budapest, HungarySeptember 7, 2023 | finance.yahoo.comPainReform Selected for Poster Presentation at the 13th Congress of the European Pain Federation in Budapest, HungarySeptember 5, 2023 | finance.yahoo.comPainReform to Participate in the H.C. Wainwright 25th Annual Global Investment Conference in New York CityAugust 30, 2023 | finance.yahoo.comPRFX - PainReform Ltd.August 11, 2023 | finance.yahoo.comPainReform Provides Business Update for the Second Quarter of 2023July 19, 2023 | finanznachrichten.dePainReform Ltd: PainReform Regains Compliance with Nasdaq Continued Listing RequirementsJuly 19, 2023 | finance.yahoo.comPainReform Regains Compliance with Nasdaq Continued Listing RequirementsJuly 14, 2023 | markets.businessinsider.comPRFX Stock: The $2.7 Million Reason PainReform Is Up 100% TodayJuly 14, 2023 | finance.yahoo.comPainReform Announces Pricing of $1.5 Million Concurrent Registered Direct Offering and Private PlacementJuly 14, 2023 | marketbeat.comTrading was temporarily halted for "PRFX" at 02:07 PM with a stated reason of "LULD pause."July 14, 2023 | marketbeat.comTrading was temporarily halted for "PRFX" at 10:07 AM with a stated reason of "LULD pause."July 14, 2023 | marketbeat.comTrading was temporarily halted for "PRFX" at 10:07 AM with a stated reason of "LULD pause."July 14, 2023 | marketbeat.comTrading was temporarily halted for "PRFX" at 10:07 AM with a stated reason of "LULD pause."July 14, 2023 | marketbeat.comTrading was temporarily halted for "PRFX" at 10:07 AM with a stated reason of "LULD pause."July 14, 2023 | marketbeat.comTrading was temporarily halted for "PRFX" at 09:07 AM with a stated reason of "LULD pause."July 14, 2023 | marketbeat.comTrading was temporarily halted for "PRFX" at 09:07 AM with a stated reason of "LULD pause."July 14, 2023 | marketbeat.comTrading was temporarily halted for "PRFX" at 09:07 AM with a stated reason of "LULD pause."July 14, 2023 | marketbeat.comTrading was temporarily halted for "PRFX" at 09:07 AM with a stated reason of "LULD pause."July 12, 2023 | marketwatch.comPainReform Shares Unwind From Tuesday Surge After PricingJuly 12, 2023 | msn.comPainReform (NASDAQ:PRFX) Tanks on $2.7M Registered Direct OfferingJuly 12, 2023 | finance.yahoo.comPainReform Announces Pricing of $2.7 Million Concurrent Registered Direct Offering and Private PlacementJuly 11, 2023 | benzinga.comWhat's Going On With PainReform (PRFX) Stock?July 11, 2023 | marketbeat.comTrading was temporarily halted for "PRFX" at 03:07 PM with a stated reason of "LULD pause." Get PainReform News Delivered to You Automatically Sign up to receive the latest news and ratings for PRFX and its competitors with MarketBeat's FREE daily newsletter. Email Address [FREE Ticket] 27 Crypto Experts Reveal Their #1 Picks (Ad)Are you monitoring 13,217 cryptocurrencies everyday? If not, you could miss the ONE that can make you wealthy beyond your wildest dreams. You see, while Bitcoin and Ethereum steal all the headlines… It’s often the cryptos flying under the radar that turn small stakes into life-changing windfalls. Claim your free seat by clicking here now. PRFX Media Mentions By Week PRFX Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. PRFX News Sentiment▼0.860.55▲Average Medical News Sentiment PRFX News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. PRFX Articles This Week▼61▲PRFX Articles Average Week Get PainReform News Delivered to You Automatically Sign up to receive the latest news and ratings for PRFX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: BPTH News Today ATNF News Today QLGN News Today INM News Today ALLR News Today PXMD News Today PBLA News Today ADXS News Today GLMD News Today BDRX News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:PRFX) was last updated on 5/16/2024 by MarketBeat.com Staff From Our PartnersGold Set to EXPLODE!Gold Safe ExchangeWith revenue forecasted to grow dramatically in 2024 and beyond, this company should be on your radarStocks NewsWhy Is Gold On a MASSIVE rally? Huge AlertsThe Overlooked Retirement Asset You Probably Don’t OwnCrypto 101 MediaCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Banyan Hill PublishingCharles Payne Demystifies OptionsUnstoppable ProsperityBiden FINISHED On June 13th?Paradigm PressHow Biden has already won 2024Porter & Company Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding PainReform Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
